Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease

Figure 4

The eGRF for the patients with renal function in stage II or III. (a) For the 32 patients in stage II in LdT-R arm, eGRF was improved from baseline 74.7 ± 6.9 ml/min to 79.7 ± 8.7 ml/min at 10 months of LdT administration ( = 0.007) and 84.2 ± 16.6 ml/min at 12 months of LdT administration ( = 0.002). Compared to LAM-C arm, eGFR became different from 10 months after LdT administration. (b) For the 20 patients in stage III, eGRF was improved from baseline 48.2 ± 7.3 ml/min to 54.4 ± 14.1 ml/min at 10 months of LdT administration ( = 0.002) and 59.7 ± 11.8 ml/min at 12 months of LdT administration ( < 0.001). Compared to LAM-C arm, eGFR became improved at 12 months after LdT administration.

(a)

(b)